Meet Zepatier
February 2, 2016
Crohn’s Disease and Ulcerative Colitis Relapse triggered by Sleep Disturbances
February 2, 2016
Show all

FDA approves Merck’s new hepatitis C pill

A new medication for the treatment of hepatitis C received FDA approval on January 28, 2016.

U.S. regulators on Thursday approved a new once-daily pill for the liver-destroying hepatitis C virus made by Merck & Co Inc, which said it will sell the drug at a lower list price than its competitors.

The list price for Zepatier will be $54,600 for a 12-week regimen, which Merck said it expects “to be in the range of net prices” for comparable treatments.

Gilead Sciences Inc, which secured an early lead in the lucrative market for oral hepatitis C drugs with the $1,000-per-pill Sovaldi, currently sells an enhanced version of that drug as a single-tablet regimen called Harvoni at a list price of $94,500. AbbVie Inc followed in late 2014 with a multi-pill regimen. Nevertheless, AbbVie secured exclusive contracts with payers such as pharmacy benefit manager Express Scripts Holding Co, forcing Gilead to discount its own contract prices.

Gilead has continued to dominate the market with hepatitis C drug sales of more than $14 billion in the first nine months of 2015.

The Food and Drug Administration approved Zepatier, with or without the older antiviral drug ribavirin, for patients infected with the most common form of hepatitis C, genotype 1, as well as the less common genotype 4.

Read Full Article: FDA approves Merck’s new hepatitis C pill


The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.